Generic name |
benralizumab |
---|---|
Strength |
30 mg/mL |
Form |
solution for subcutaneous injection |
Special Authority criteria |
Approval period |
---|---|
Initial For the add-on maintenance treatment of adult patients with severe eosinophilic asthma meeting ALL the following criteria:
a) blood eosinophil count of ≥300 cells/µl in the past 12 months and the patient has experienced 2 or more clinically significant asthma exacerbations3 in the past 12 months OR b) blood eosinophil count of ≥150 cells/µl and is currently receiving maintenance treatment with oral corticosteroids4 |
1 year |
First renewal Renewal of coverage requested by a respirologist or allergist with expertise in treating asthma will be considered for adult patients whose:
AND
OR
|
1 year |
Second and subsequent renewal Renewal of coverage requested by a respirologist or allergist with expertise in treating asthma will be considered for adult patients whose:
AND
OR
|
1 year |